CAR T-cell therapy in patients who have previously received anticancer alkylating agent therapy
Patent Information
- Application Number
- JP2023528090
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-04
- Filing Date
- 2021-11-03
- Publication Date
- 2024-11-11
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatment methods, such as CAR-T therapy, may be suboptimal when administered sequentially after other therapies, particularly in patients with complex treatment histories, and there is a need to optimize cancer therapy administration considering prior treatments.
A method involving administering an alkylating agent, isolating peripheral blood mononuclear cells (PBMCs) at least 6 months later, determining a T cell percentage, and producing chimeric antigen receptor (CAR) T cells for administration, tailored to patients with previous alkylating agent exposure.
This approach enhances the effectiveness of CAR-T therapy by optimizing treatment timing and patient selection, improving outcomes for cancers like multiple myeloma and other B-cell related malignancies.
Abstract
Description
Technical field
[0001] Cross-reference to related applications This application is filed in U.S. Application No. 63 / 109,804 filed on November 4, 2020, U.S. Application No. 63 / 120,166 filed on December 1, 2020, and U.S. Application No. 63 / 120,166 filed on December 4, 2020. Claims the benefit of U.S. Application No. 63 / 121,658. The disclosures of each of these are incorporated herein by reference in their entirety.
[0002] References to electronically submitted sequence listings This application incorporates by reference the sequence listing filed with this application as an ASCII text file entitled "14247-619-228_SEQ_LISTING_CRF.txt" created on November 2, 2021 and having a size of 33,964 bytes.
[0003] 1.Field The disclosure presented herein relates to methods for treating tumors or cancers (eg, B cell-related cancers, eg, multiple myeloma). More specifically, the present disclosure describes chimeric antigen receptors (CARs) comprising antibodies or antigen-binding fragments thereof (e.g., anti-BCMA antibodies or antigen-binding fragments thereof), and chimeric antigen receptors (CARs) that have been genetically modified to express these CARs. Improved methods for treating tumors or cancers (eg, B cell-related cancers, eg, multiple myeloma) using immune effector cells (eg, T cells). The disclosure also provides CARs comprising antibodies or antigen-binding fragments thereof (e.g., anti-BCMA antibodies or antigen-binding fragments thereof) for treating tumors or cancers (e.g., B cell-related cancers, e.g., multiple myeloma). Relating to a method for manufacturing. The present subject matter also relates to techniques for determining optimal exposure washout periods of previous treatment regimens using time-to-event models. [Background technology]
[0004] 2.Background 2.1. Background Many options are currently available to approach the treatment of cancer, including, for example, traditional chemotherapeutic approaches, as well as immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy. In some cases, the use of one therapy may make administration of a second treatment suboptimal. Accordingly, there is a need to optimize the administration of cancer therapy (eg, CAR-T therapy) when it is administered to a patient, eg, when administered sequentially.
[0005] Additionally, in many situations, patients may change health care providers and / or change exposure plans in connection with treatment of diseases such as cancer. Patients often have extensive and variable prior treatment histories, and these prior exposures may influence the patient's current situation, such that it It can affect how you react. [Summary of the invention]
[0006] 3. Brief overview The present disclosure generally provides improved methods of treating tumors or cancers, such as B cell-related cancers, such as multiple myeloma.
[0007] In one aspect, a method of treating a tumor or cancer in a subject in need of treatment, comprising: (a) administering an alkylating agent to the subject; (b) at least about 6 months after step (a). isolating peripheral blood mononuclear cells (PBMCs) from the subject; (c) determining that at least about 20% of the PBMCs are T cells; (d) based on the determination in step (c), subsequently Provided herein are methods comprising: producing chimeric antigen receptor (CAR) T cells from PBMCs; then (e) administering the CAR T cells to a subject. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later.
[0008] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not a Revised International Staging System (R-ISS) Stage III disease.
[0009] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0010] In certain embodiments, the subject is a human.
[0011] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0012] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0013] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. (b) Based on the determination in step (a), subsequently producing chimeric antigen receptor (CAR) T cells from PBMC; and (c) administering the CAR T cells to the subject. Provided herein are methods comprising the step of: prior to step (a), the subject has previously received an alkylating agent for treatment of cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously attended step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago.
[0014] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0015] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0016] In certain embodiments, the subject is a human.
[0017] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0018] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0019] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; (b) a chimeric antigen from the PBMCs; producing receptor (CAR) T cells; then (c) administering the CAR T cells to a subject, the subject having previously received an alkylating agent for treatment of cancer; ) is performed at least about 6 months after the subject receives the alkylating agent. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) extracting chimeras from the PBMCs based on the determination in step (a). The method further includes the step of subsequently producing antigen receptor (CAR) T cells. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0020] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0021] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0022] In certain embodiments, the subject is a human.
[0023] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0024] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0025] In another embodiment, a method of treating a tumor or cancer in a subject in need of treatment, wherein the subject has been administered an alkylating agent, and (a) the subject has been administered an alkylating agent for about 6 years prior to this determining step. (b) isolating peripheral blood mononuclear cells (PBMC) from the subject; (c) chimeric antigen receptor (CAR) T cells from the PBMC; Provided herein are methods comprising: producing a CAR T cell; and then (d) administering the CAR T cell to a subject. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0026] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0027] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0028] In certain embodiments, the subject is a human.
[0029] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0030] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0031] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, wherein the subject has been administered an alkylating agent, and the method comprises: (a) mononuclear peripheral blood mononuclear cells (PBMC) from the subject; (b) producing chimeric antigen receptor (CAR) T cells from PBMCs; and then (c) administering the CAR T cells to the subject, wherein at the time of isolation, the subject is at least about 6 Provided herein are methods in which it has been determined that the alkylating agent has been administered within the past month. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have received an alkylating agent at least about 14 months ago.
[0032] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0033] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0034] In certain embodiments, the subject is a human.
[0035] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.
[0036] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0037] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, the subject receiving an alkylating agent, the alkylating agent produced from peripheral blood mononuclear cell PBMCs isolated from the patient. administering to the subject T cells expressing a chimeric antigen receptor (CAR T cells), at least about 6 months prior to the time the PBMCs are isolated. Provided herein are methods that ultimately receive an alkylating agent. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more Last received an alkylating agent at least about 13 months ago, or at least about 14 months ago.
[0038] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0039] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0040] In certain embodiments, the subject is a human.
[0041] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0042] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0043] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, the subject receiving an alkylating agent, the alkylating agent produced from peripheral blood mononuclear cell PBMCs isolated from the patient. CAR T cells, wherein when the PBMCs are isolated, the PBMCs contain at least 20% T cells. provided.
[0044] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0045] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0046] In certain embodiments, the subject is a human.
[0047] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0048] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0049] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising the steps of: (a) administering to the subject an alkylating agent; b) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after step (a); (c) determining that at least about 20% of the PBMCs are T cells; d) based on the determination in step (c), subsequently producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMCs; then (e) administering the CAR T cells to the subject; Provided herein are methods comprising the steps of: In certain embodiments, step (b) includes at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about conducted after about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months.
[0050] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0051] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0052] In certain embodiments, the subject is a human.
[0053] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0054] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0055] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0056] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising: (a) removing peripheral blood mononuclear cells (PBMCs) from the subject; isolating and determining that at least about 20% of the PBMCs are T cells; (b) based on the determination in step (a), subsequently producing BCMA-directed chimeric antigen receptor (CAR) T cells ( and (c) administering the CAR T cells to a subject, and prior to step (a), the subject has previously received an alkylating agent for treatment of cancer. A method is provided herein. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago.
[0057] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0058] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0059] In certain embodiments, the subject is a human.
[0060] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0061] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0062] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0063] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising: (a) removing peripheral blood mononuclear cells (PBMCs) from the subject; (b) producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMC; (c) administering the BCMA CAR T cells to a subject; Provided herein are methods wherein the patient has previously received an alkylating agent for treatment of cancer, and step (a) is performed at least about 6 months after the subject has received the alkylating agent. be done. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) subsequently comprises determining that at least about 20% of the PBMCs are T cells; The method further includes the step of producing chimeric antigen receptor (CAR) T cells from. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0064] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0065] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0066] In certain embodiments, the subject is a human.
[0067] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0068] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0069] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0070] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, the subject administering an alkylating agent for treatment of the cancer. (a) determining that the subject has not received an alkylating agent for less than about 6 months prior to this determining step; (b) obtaining peripheral blood mononuclear cells (PBMCs) from the subject; isolating, the isolating step being performed at least 6 months after the alkylating agent was administered to the subject; (c) a chimeric antigen receptor (CAR) directed to BCMA from PBMCs; Provided herein are methods comprising: producing a T cell (BCMA CAR T cell); and then (d) administering the BCMA CAR T cell to a subject. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0071] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0072] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0073] In certain embodiments, the subject is a human.
[0074] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0075] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0076] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0077] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent, the method comprising: (a) Isolating peripheral blood mononuclear cells (PBMCs) from the subject; (b) producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMCs; then (c) BCMA Provided herein are methods comprising administering a CAR T cell to a subject, wherein, at the time of isolation, it is determined that the subject has been administered an alkylating agent at least about 6 months previously. . In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have been administered an alkylating agent at least about 14 months ago.
[0078] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0079] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0080] In certain embodiments, the subject is a human.
[0081] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0082] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0083] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0084] In another aspect, a method of treating cancer caused by cells expressing a B-cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent and receiving an alkylating agent from the patient. administering to the subject BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) produced from isolated peripheral blood mononuclear cell PBMCs, when the PBMCs are isolated; Provided herein are methods, wherein the subject last received an alkylating agent at least about 6 months before the time the PBMCs were isolated. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more Last received an alkylating agent at least about 13 months ago, or at least about 14 months ago.
[0085] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0086] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0087] In certain embodiments, the subject is a human.
[0088] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0089] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0090] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0091] In another aspect, a method of treating cancer caused by cells expressing a B-cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent and receiving an alkylating agent from the patient. administering to the subject BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) produced from isolated peripheral blood mononuclear cell PBMCs, when the PBMCs are isolated; Provided herein are methods wherein the PBMCs contain at least about 20% T cells.
[0092] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0093] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0094] In certain embodiments, the subject is a human.
[0095] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0096] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0097] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0098] In another embodiment, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising the steps of: (a) administering an alkylating agent to the subject for treatment of a tumor or cancer; (b) (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after; and then (c) producing chimeric antigen receptor (CAR) T cells from the PBMCs. Provided herein. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later.
[0099] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0100] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0101] In certain embodiments, the subject is a human.
[0102] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.
[0103] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0104] In another aspect, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. and (b) subsequently producing chimeric antigen receptor (CAR) T cells from PBMCs based on the determination in step (b); Provided herein are methods in which the patient has previously received an alkylating agent for the treatment of a tumor or cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago.
[0105] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0106] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0107] In certain embodiments, the subject is a human.
[0108] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0109] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0110] In another embodiment, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising the steps of: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; the step of producing antigen receptor (CAR) T cells; the subject has previously received an alkylating agent for tumor or cancer treatment; step (a) Provided herein are methods that are performed after at least about 6 months. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) subsequently comprises determining that at least about 20% of the PBMCs are T cells; The method further includes the step of producing chimeric antigen receptor (CAR) T cells from. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0111] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0112] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0113] In certain embodiments, the subject is a human.
[0114] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0115] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0116] In another aspect, a method of producing a chimeric antigen receptor (CAR) T cell from a subject, the subject being administered an alkylating agent for the treatment of a tumor or cancer, the subject comprising: a. determining that the subject has not been administered an alkylating agent for less than about 6 months prior to determining; b. isolating peripheral blood mononuclear cells (PBMCs) from the subject; and c. Provided herein are methods comprising producing receptor (CAR) T cells. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0117] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0118] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0119] In certain embodiments, the subject is a human.
[0120] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0121] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0122] In another aspect, a method of producing a chimeric antigen receptor (CAR) T cell from a subject, the subject receiving an alkylating agent for the treatment of a tumor or cancer, the method comprising: isolating blood mononuclear cells (PBMCs); then (b) producing chimeric antigen receptor (CAR) T cells from the PBMCs; at the time of isolation, the subject has been at least about 6 months old. Provided herein are methods in which it is determined that an alkylating agent has been administered. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have received an alkylating agent at least about 14 months ago.
[0123] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0124] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0125] In certain embodiments, the subject is a human.
[0126] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0127] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0128] In another aspect, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. and (b) subsequently manufacturing CAR T cells from the PBMCs based on the determination in step (a); Provided herein are methods in which the method includes a curing agent. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago.
[0129] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0130] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0131] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0132] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0133] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0134] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0135] In certain embodiments, the subject is a human.
[0136] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0137] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0138] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) administering an alkylating agent to the subject for the treatment of cancer; (b) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after step (a); and (c) producing BCMA CAR T cells from the PBMCs. , methods are provided herein. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later.
[0139] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0140] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0141] In certain embodiments, the subject is a human.
[0142] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0143] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0144] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0145] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; , determining that at least about 20% of the PBMCs are T cells; then (b) based on the determination in step (a), subsequently producing BCMA CAR T cells from the PBMCs; step (a) Provided herein are methods in which the subject has previously received an alkylating agent for treatment of cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago.
[0146] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0147] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0148] In certain embodiments, the subject is a human.
[0149] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0150] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0151] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0152] In another aspect, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; and then (b) producing BCMA CAR T cells from PBMC; the subject has previously received an alkylating agent for treatment of cancer; step (a) Provided herein are methods that are carried out at least about 6 months after receiving. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) subsequently comprises determining that at least about 20% of the PBMCs are T cells; The method further includes the step of producing chimeric antigen receptor (CAR) T cells from. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0153] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0154] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0155] In certain embodiments, the subject is a human.
[0156] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the subject receiving an alkylating agent for the treatment of cancer. a. determining that the subject has not been administered an alkylating agent for less than about 6 months prior to this determining step; b. isolating peripheral blood mononuclear cells (PBMC) from the subject; provided herein is a method comprising: then producing BCMA CAR T cells from c.PBMC. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0157] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0158] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0159] In certain embodiments, the subject is a human.
[0160] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0161] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0162] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0163] In another embodiment, a method of producing a BCMA-directed chimeric antigen receptor (CAR) T cell (c) from a subject, the subject being administered an alkylating agent for the treatment of cancer (a ) isolating peripheral blood mononuclear cells (PBMCs) from the subject; and then (b) producing BCMA T cells from the PBMCs; at the time of isolation, the subject has been alkylated for at least about 6 months. Provided herein are methods in which it is determined that an agent has been administered. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have received an alkylating agent at least about 14 months ago.
[0164] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0165] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0166] In certain embodiments, the subject is a human.
[0167] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; determining that at least about 20% of the PBMCs are T cells; and then (b) subsequently producing BCMA CAR T cells from the PBMCs based on the determination in step (a); Provided herein are methods for treating cancers caused by BCMA-expressing cells that have received an alkylating agent. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago, received an alkylating agent.
[0168] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0169] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0170] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0171] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0172] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0173] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0174] In certain embodiments, the subject is a human.
[0175] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0176] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0177] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0178] In another aspect, a method of determining whether a subject having cancer can be treated with CAR T therapy, the method comprising: determining the percentage of CD3+ T cells in the subject relative to the number of PMBC; CAR T therapy will not be administered to a subject if (i) the subject has less than approximately 20% CD3+ T cells relative to the number of PBMCs, and (ii) the subject has approximately 20% CD3+ T cells relative to the number of PBMCs. Provided herein are methods of administering CAR T therapy to a subject if the subject has greater than % CD3+ T cells. In certain embodiments, the CD3+ T cells are CD45+ / CD3+ T cells.
[0179] In another aspect, a method of treating cancer in a subject comprising determining that the percentage of CD3+ T cells in the subject relative to the number of PMBC is greater than about 20% and administering CAR T therapy to the subject. provided herein. In certain embodiments, the CD3+ T cells are CD45+ / CD3+ T cells.
[0180] In general, the TTE models described herein assume that temporal data about an event and its previous event are available, and the time between that event and its previous event, e.g. exposure, e.g. time between previous treatments (i.e. washout time).
[0181] In an interrelated aspect, the optimal washout period for initiating therapy for treatment of a condition in a subject after a prior exposure includes receiving prior treatment history data for each of the plurality of subjects. It can be determined by Left-censoring data, including washout periods and events or censoring, can then be derived for each of the subjects from previous treatment history data. The time scale of the left-censored treatment data is then reversed to obtain right-censored treatment data. The right-censored treatment data are then applied to a time-event (TTE) model that relates one or more variables of interest to time since exposure to a previous exposure. Compute maximally selected log-rank statistics across multiple cutoffs within predefined percentile ranges for continuous variables within one or more variables of interest. One or more variables and associated cutoffs for continuous variables are then identified that have a maximally selected log-rank statistic below a first predefined threshold. Test statistics (eg, Cox proportional hazards statistics, etc.) for each (n-1) stratum relative to the reference stratum are then calculated for the ordinal or categorical variables within the one or more variables of interest. One or more ordinal or categorical variables and associated strata are identified that have a test statistic (eg, Cox proportional hazards statistic, etc.) less than a second predefined threshold relative to a reference stratum. The optimum for treatment is then determined based on a cutoff for the median subject value below the predefined threshold and the median subject value above the predefined threshold, with a minimum value below a predefined threshold. Determine the washout period.
[0182] A determined washout period can be provided. In this regard, displaying the determined optimal washout period on an electronic visual display, storing the determined optimal washout period in a physical persistence, storing the determined optimal washout period in memory. The method may include one or more of loading or transmitting the determined optimal washout period over a network to a remote computing device.
[0183] The TTE model may be a proportional hazards model, such as a Cox proportional hazards model.
[0184] One or more of the steps of accepting, deriving, reversing, applying, first or second calculating, first or second identifying, and determining includes at least one and at least one data processor forming part of a computing device.
[0185] The previous exposure may be a previous treatment.
[0186] The previous exposure and treatment may be different types of treatment.
[0187] The previous exposure may be to treat a condition different from the condition treated by said treatment.
[0188] The previous exposure may be to treat the same condition treated by said treatment.
[0189] The previous exposure and treatment may be for treating the same condition and are of the same type of treatment.
[0190] The treatment may be a second or subsequent (eg, third, fourth, fifth, sixth, seventh, or subsequent) line of treatment, and the prior exposure is an earlier line of treatment.
[0191] The information provided by the TTE model can inform (i) when a subject should receive treatment after a previous exposure or (ii) exclusion criteria in clinical trials.
[0192] The treatment and / or previous exposure may be radiation therapy, chemotherapy, immunotherapy, surgery, transplantation, gene therapy, or cell therapy.
[0193] The condition may be cancer, an immune disease (eg, an autoimmune disease), a cardiovascular disease, a fibrosis, an infectious disease, or a neurological condition.
[0194] The condition can be a condition that can be treated by stimulating the immune system, such as cancer and infectious diseases, and the treatment is a therapy that stimulates or enhances the immune system, such as immunotherapy and cell therapy.
[0195] The condition may be cancer and the treatment may be cell therapy, such as CAR T.
[0196] The previous exposure may be a previous treatment, and the previous treatment may be a previous cancer treatment.
[0197] The cancer may be multiple myeloma and the treatment may be a BCMA CAR T (e.g. a CAR comprising SEQ ID NO: 37 or a nucleic acid encoding a CAR of SEQ ID NO: 9 or 37) and the previous treatment may be multiple myeloma. May be previous cancer treatment for myeloma.
[0198] The previous exposure may be alkylating agent therapy.
[0199] In some variants, the previous exposure is not a previous treatment.
[0200] Previous exposure may be an event that can negatively impact treatment.
[0201] A previous exposure may be a previous condition.
[0202] The previous exposure may be an inflammatory condition or an infectious disease (eg, a viral infection, eg, a COVID-19 infection).
[0203] In an interrelated aspect, the condition in the subject is the step of administering to the subject a treatment to treat the condition, wherein the treatment is administered after a previous exposure, and when the treatment is administered after the previous exposure ( ie washout period) calculated using the methods provided herein.
[0204] In a further interrelated aspect, the condition in the subject is determined by administering a treatment to the subject to treat the condition, wherein the treatment is performed after a previous exposure using a method provided herein. The treatment can be carried out by administering a process that is administered at a time after the previous exposure determined by the
[0205] In further interrelated aspects, the system includes at least one data processor and a memory that stores instructions that, when executed by the at least one data processor, implement the methods provided herein. good.
[0206] In a further interrelated aspect, the non-transitory computer program product can store instructions that, when executed by at least one computing device, implement the methods provided herein.
[0207] In general, the TTE models described herein assume that temporal data about an event and its previous event are available, and the time between that event and its previous event, e.g. exposure, e.g. time between previous treatments (i.e. washout time).
[0208] Aspects of the present subject matter provide non-computer storage instructions that, when executed by one or more data processors of one or more computing systems, cause at least one data processor to perform the operations herein. Can be embodied in a temporary computer program product (ie, a physically embodied computer program product). Similarly, the present subject matter may be embodied in a computer system that includes one or more data processors and a memory coupled to the one or more data processors. The memory may temporarily or permanently store instructions that cause at least one processor to perform one or more of the operations described herein. Additionally, the method can be performed by one or more data processors within a single computing system or distributed across two or more computing systems. Such computing systems may be coupled, including but not limited to coupling across networks (e.g., the Internet, wireless wide area networks, local area networks, wide area networks, wired networks, etc.). may exchange data and / or commands or other instructions, etc., such as via a direct connection between one or more of the multiple computing systems, etc.
[0209] 4. Brief description of the drawing [Brief explanation of the drawing]
[0210]
Figure 1
[0211] 5. Brief explanation of sequence number SEQ ID NOs: 1-3 describe the amino acid sequences of exemplary light chain CDR sequences for BCMA CARs contemplated herein.
[0212] SEQ ID NOs: 4-6 describe the amino acid sequences of exemplary heavy chain CDR sequences for BCMA CARs contemplated herein.
[0213] SEQ ID NO: 7 describes the amino acid sequence of an exemplary light chain sequence for a BCMA CAR contemplated herein.
[0214] SEQ ID NO: 8 describes the amino acid sequence of an exemplary heavy chain sequence for a BCMA CAR contemplated herein.
[0215] SEQ ID NO: 9 describes the amino acid sequence of an exemplary BCMA CAR contemplated herein with a signal peptide (amino acids 1-22). The amino acid sequence of the mature form of BCMA02 is set forth in SEQ ID NO:37.
[0216] SEQ ID NO: 10 describes a polynucleotide sequence encoding an exemplary BCMA CAR contemplated herein.
[0217] SEQ ID NO: 11 describes the amino acid sequence of human BCMA.
[0218] SEQ ID NOS: 12-22 describe the amino acid sequences of various linkers.
[0219] SEQ ID NOS: 23-35 describe the amino acid sequences of the protease cleavage site and the self-cleavable polypeptide cleavage site.
[0220] SEQ ID NO: 36 describes the polynucleotide sequence of a vector encoding an exemplary BCMA CAR. See Table 1.
[0221] SEQ ID NO: 37 describes the amino acid sequence of an exemplary mature BCMA CAR (ie, without a signal sequence) contemplated herein.
[0222] SEQ ID NO: 38 describes the amino acid sequence of BCMA02 scFv.
[0223] Table 1: List of arrays: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]
[0224] 6.Detailed explanation 6.1. Methods for treating tumors or cancer using chimeric antigen receptor (CAR) T cells and methods for producing CAR T cells The disclosure presented herein generally relates to improved methods for treating tumors or cancers, such as B cell-related diseases or cancers, including multiple myeloma. The disclosure presented herein also relates to methods of producing CAR T cells, such as BCMA directed CAR T cells (BCMA CAR T cells). As used herein, the term "B cell-related conditions" refers to conditions including inappropriate B cell activity and B cell malignancies.
[0225] Certain embodiments presented herein provide improved treatment of diseases (e.g., tumors or cancers, including multiple myeloma, or B cell-related diseases or cancers) using genetically modified immune effector cells. Regarding adoptive cell therapy. Genetic approaches offer potential ways to enhance immune recognition and elimination of cancer cells. One promising strategy is to genetically engineer immune effector cells to express chimeric antigen receptors (CARs) that redirect cytotoxicity toward cancer cells.
[0226] Improvements in administering CAR T cell therapy for use in subjects (e.g., patients) who have been administered an alkylating agent (e.g., for chemotherapy) before the CAR T cell therapy disclosed herein is administered. The method described includes a method in which the step of isolating peripheral blood mononuclear cells (PBMCs) from a subject is performed after a period after the alkylating agent has been administered to the subject (i.e., a "washout" period). include. Improved methods of administering CAR T cell therapy disclosed herein for use in subjects who have been administered an alkylating agent (e.g., for chemotherapy) before CAR T cell therapy is administered include , genetically modified immune effector cells (e.g. CAR T cells) that can be easily expanded and exhibit long-term persistence in vivo, and e.g. B cell maturation antigens (BCMA, CD269 or the tumor necrosis factor receptor subfamily). , member 17; also known as TNFRSF17) can be used with genetically modified immune effector cells (e.g. CAR T cells) to reduce impairment of humoral immunity by targeting B cells expressing . Also disclosed herein are improved methods of producing CAR T cells (eg, BCMA CAR T cells) from PBMCs isolated from patients who have been administered alkylating agents (eg, for chemotherapy).
[0227] BCMA is a member of the tumor necrosis factor receptor superfamily (e.g. Thompson et al., J. Exp. Medicine, 192(1): 129-135, 2000 and Mackay et al., Annu. Rev. Immunol, 21: 231-264, 2003). BCMA binds B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) (see, eg, Mackay et al., 2003 and Kalled et al., Immunological Reviews, 204: 43-54, 2005). Among benign cells, BCMA has been reported to be mainly expressed in plasma cells and a subset of mature B cells (e.g. Laabi et al., EMBO J., 77(1): 3897-3904, 1992; Laabi et al., Nucleic Acids Res., 22(7): 1147-1154,, 1994; Kalled et al., 2005; O'Connor et al., J. Exp. Medicine, 199(1): 91-97, 2004; and Ng et al., J. Immunol., 73(2): 807-817, 2004). Mice deficient in BCMA are healthy and have normal numbers of B cells, but survival of long-lived plasma cells is impaired (e.g. O'Connor et al., 2004; Xu et al., Mol. Cell. Biol., 21(12): 4067-4074, 2001; and Schiemann et al., Science, 293(5537): 2 111-21 14, 2001). BCMA RNA has been universally detected in multiple myeloma cells and other lymphomas, and BCMA protein has been detected by some researchers on the surface of plasma cells from multiple myeloma patients (e.g. Novak et al. et al., Blood, 103(2): 689-694, 2004; Neri et al., Clinical Cancer Research, 73(19): 5903-5909, 2007; Bellucci et al., Blood, 105(10): 3945 -3950, 2005; and Moreaux et al., Blood, 703(8): 3148-3157, 2004).
[0228] In one embodiment, a method of treating a tumor or cancer, e.g., in a subject in need of treatment, comprising: (a) administering an alkylating agent to the subject; (b) for at least about 6 months of step (a). (c) determining that at least about 20% of the PBMCs are T cells; (d) based on the determination in step (c), subsequently Provided herein are methods comprising: producing chimeric antigen receptor (CAR) T cells from PBMC; and then (e) administering the CAR T cells to a subject. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later.
[0229] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0230] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells, such as CD45+ / CD3+ T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells, eg, CD45+ / CD3+ T cells.
[0231] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0232] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0233] In certain embodiments, step (b) is performed at least about 6 months to about 14 months after step (a), at least about 6 months to about 13 months after step (a), and at least about 6 months to about 13 months after step (a). at least about 6 months to about 12 months after step (a), at least about 6 months to about 10 months after step (a), after at least about 6 months to about 10 months after step (a); ), at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months after step (a). Ru. In certain embodiments, step (b) is performed at least about 7 months to about 14 months after step (a), at least about 8 months to about 14 months after step (a), and at least about 8 months to about 14 months after step (a). at least about 9 months to about 14 months after step (a), at least about 11 months to about 14 months after step (a), after at least about 11 months to about 14 months after step (a), It is carried out at least about 12 months to about 14 months after a), or at least about 13 months to about 14 months after step (a).
[0234] In another specific embodiment, step (b) is performed at least about 4 months or 5 months to about 14 months after step (a), at least about 4 months or 5 months after step (a). After about 13 months, at least about 4 months or 5 months to about 12 months after step (a), at least about 4 months or 5 months to about 11 months after step (a), after step (a) At least about 4 months or 5 months to about 10 months after a), at least about 4 months or 5 months to about 9 months after step (a), at least about 4 months after step (a) or 5 months to about 8 months after, at least about 4 months or 5 months to about 7 months after step (a), or at least about 4 months or 5 months to about 6 months after step (a) It will be implemented in a month.
[0235] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma.
[0236] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0237] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0238] In certain embodiments, the subject is a human.
[0239] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.
[0240] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0241] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. (b) based on the determination in step (a), subsequently producing chimeric antigen receptor (CAR) T cells from PBMC; and (c) administering the CAR T cells to the subject. Provided herein are methods comprising the step of: prior to step (a), the subject has previously received an alkylating agent for treatment of cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago. In certain embodiments, the subject has previously undergone at least about 6 months to about 14 months before step (a), at least about 6 months to about 13 months before step (a), At least about 6 months to about 12 months before step (a), at least about 6 months to about 11 months before step (a), at least about 6 months to about 10 months before step (a), step (a) at least about 6 months to about 9 months before, at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months before step (a). was receiving medication. In certain embodiments, the subject has previously undergone at least about 7 months to about 14 months before step (a), at least about 8 months to about 14 months before step (a), At least about 9 months to about 14 months before step (a), at least about 10 months to about 14 months before step (a), at least about 11 months to about 14 months before step (a), step (a) or at least about 13 months to about 14 months before step (a).
[0242] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0243] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0244] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0245] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0246] In another specific embodiment, the subject has previously performed at least about 4 months or 5 months to about 14 months prior to step (a), at least about 4 months or 5 months to about 14 months prior to step (a). 13 months before, at least about 4 months or 5 months to about 12 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), ) at least about 4 months or 5 months to about 10 months before step (a), at least about 4 months or 5 months to about 9 months before step (a), or at least about 4 months before step (a) or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before step (a), or at least about 4 months or 5 months to about 6 months before step (a) He had received an alkylating agent a month ago.
[0247] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0248] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0249] In certain embodiments, the subject is a human.
[0250] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0251] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0252] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; (b) a chimeric antigen from the PBMCs; producing receptor (CAR) T cells; then (c) administering the CAR T cells to a subject, the subject having previously received an alkylating agent for treatment of cancer; ) is performed at least about 6 months after the subject receives the alkylating agent. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) extracting chimeras from the PBMCs based on the determination in step (a). The method further includes the step of subsequently producing antigen receptor (CAR) T cells. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, and at least about 14 months. In certain embodiments, step (a) occurs at least about 6 months to about 14 months after the subject received the alkylating agent, at least about 6 months to about 13 months after the subject received the alkylating agent. at least about 6 months to about 12 months after the subject received an alkylating agent, at least about 6 months to about 11 months after the subject received an alkylating agent, after the subject received an alkylating agent At least about 6 months to about 10 months after the subject received an alkylating agent, at least about 6 months to about 9 months after the subject received an alkylating agent, at least about 6 months to about 8 months after the subject received an alkylating agent or at least about 6 months to about 7 months after the subject received the alkylating agent. In certain embodiments, step (a) occurs at least about 7 months to about 14 months after the subject received the alkylating agent, at least about 8 months to about 14 months after the subject received the alkylating agent. after the subject received an alkylating agent, at least about 9 months to about 14 months after the subject received an alkylating agent, at least about 10 months to about 14 months after the subject received an alkylating agent, after the subject received an alkylating agent after at least about 11 months to about 14 months, after at least about 12 months to about 14 months after the subject received an alkylating agent, or after at least about 13 months to about 14 months after the subject received an alkylating agent. It will be implemented in a month.
[0253] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0254] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0255] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0256] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0257] In another specific embodiment, step (a) comprises at least about 4 months or from 5 months to about 14 months after the subject received the alkylating agent, at least about 4 months after the subject received the alkylating agent. month or 5 months to about 13 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 12 months after the subject has received an alkylating agent, at least about 4 months or after the subject has received an alkylating agent 5 months to about 11 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 10 months after the subject has received an alkylating agent, at least about 4 months or 5 months after the subject has received an alkylating agent ~9 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent Performed about 7 months later, or at least about 4 months or 5 months to about 6 months after the subject received the alkylating agent.
[0258] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0259] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0260] In certain embodiments, the subject is a human.
[0261] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0262] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0263] In another embodiment, a method of treating a tumor or cancer in a subject in need of treatment, wherein the subject has been administered an alkylating agent, and (a) the subject has been administered an alkylating agent for about 6 years prior to this determining step. (b) isolating peripheral blood mononuclear cells (PBMC) from the subject; (c) chimeric antigen receptor (CAR) T cells from the PBMC; Provided herein are methods comprising: producing a CAR T cell; and then (d) administering the CAR T cell to a subject. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0264] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0265] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0266] In certain embodiments, the subject is a human.
[0267] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.
[0268] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0269] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, wherein the subject has been administered an alkylating agent, and the method comprises: (a) mononuclear peripheral blood mononuclear cells (PBMC) from the subject; (b) producing chimeric antigen receptor (CAR) T cells from PBMCs; and then (c) administering the CAR T cells to the subject, wherein at the time of isolation, the subject is at least about 6 Provided herein are methods in which it has been determined that the alkylating agent has been administered within the past month. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have received an alkylating agent at least about 14 months ago. In certain embodiments, the subject is at least about 6 months to about 14 months ago, at least about 6 months to about 13 months ago, at least about 6 months to about 12 months ago, at least about 6 months ago ~about 11 months ago, at least about 6 months to about 10 months ago, at least about 6 months to about 9 months ago, at least about 6 months to about 8 months ago, or at least about 6 months ago It has been determined that he received an alkylating agent approximately 7 months ago. In certain embodiments, the subject is at least about 7 months to about 14 months ago, at least about 8 months to about 14 months ago, at least about 9 months to about 14 months ago, at least about 10 months ago. ~about 14 months ago, at least about 11 months to about 14 months ago, at least about 12 months to about 14 months ago, or at least about 13 months to about 14 months ago: It has been decided that
[0270] In another specific embodiment, the subject is at least about 4 or 5 months old to about 14 months old, at least about 4 months or 5 months old to about 13 months old, at least about 4 months or 5 months old month to about 12 months ago, at least about 4 or 5 months to about 11 months ago, at least about 4 or 5 months to about 10 months ago, at least about 4 or 5 months ago ~about 9 months ago, at least about 4 or 5 months to about 8 months ago, at least about 4 or 5 months to about 7 months ago, or at least about 4 or 5 months ago It has been determined that he was given an alkylating agent approximately 6 months ago.
[0271] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0272] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0273] In certain embodiments, the subject is a human.
[0274] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of CAR T cells prior to administration of CAR T cells to the subject.
[0275] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0276] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, the subject receiving an alkylating agent, the alkylating agent produced from peripheral blood mononuclear cell PBMCs isolated from the patient. administering to the subject T cells expressing a chimeric antigen receptor (CAR T cells), at least about 6 months prior to the time the PBMCs are isolated. Provided herein are methods that ultimately receive an alkylating agent. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more Last received an alkylating agent at least about 13 months ago, or at least about 14 months ago.
[0277] In another specific embodiment, the subject is at least about 4 months or 5 months to about 14 months before, at least about 4 months or 5 months to about 13 months before the time the PBMCs are isolated. at least about 4 months or 5 months to about 12 months before the time the PBMCs are isolated; at least about 4 months or 5 months to about 11 months before the time the PBMCs are isolated; at least about 4 months or 5 months to about 10 months before the PBMCs are isolated; at least about 4 months or 5 months to about 9 months before the PBMCs are isolated; about 4 months or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before the time the PBMCs are isolated, or at least about 4 months before the time the PBMCs are isolated. Last received an alkylating agent in the last month or 5 to 6 months ago.
[0278] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0279] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0280] In certain embodiments, the subject is a human.
[0281] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0282] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0283] In another aspect, a method of treating a tumor or cancer in a subject in need of treatment, the subject receiving an alkylating agent, the alkylating agent produced from peripheral blood mononuclear cell PBMCs isolated from the patient. CAR T cells, wherein when the PBMCs are isolated, the PBMCs comprise at least about 20% T cells. provided by.
[0284] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0285] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0286] In certain embodiments, the subject is a human.
[0287] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMCs for production of CAR T cells prior to administration of CAR T cells to the subject.
[0288] In certain embodiments, CAR T cells are administered by intravenous infusion.
[0289] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising the steps of: (a) administering to the subject an alkylating agent; b) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after step (a); (c) determining that at least about 20% of the PBMCs are T cells; d) based on the determination in step (c), subsequently producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMC; then (e) administering the CAR T cells to the subject; Provided herein are methods comprising the steps of: In certain embodiments, step (b) includes at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about conducted after about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months. In certain embodiments, step (b) is performed at least about 6 months to about 14 months after step (a), at least about 6 months to about 13 months after step (a), and at least about 6 months to about 13 months after step (a). at least about 6 months to about 12 months after step (a), at least about 6 months to about 10 months after step (a), after at least about 6 months to about 10 months after step (a); ), at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months after step (a). Ru. In certain embodiments, step (b) is performed at least about 7 months to about 14 months after step (a), at least about 8 months to about 14 months after step (a), and at least about 8 months to about 14 months after step (a). at least about 9 months to about 14 months after step (a), at least about 11 months to about 14 months after step (a), after at least about 11 months to about 14 months after step (a), It is carried out at least about 12 months to about 14 months after a), or at least about 13 months to about 14 months after step (a).
[0290] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0291] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0292] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0293] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0294] In another specific embodiment, step (b) is performed at least about 4 months or 5 months to about 14 months after step (a), at least about 4 months or 5 months after step (a). After about 13 months, at least about 4 months or 5 months to about 12 months after step (a), at least about 4 months or 5 months to about 11 months after step (a), after step (a) At least about 4 months or 5 months to about 10 months after a), at least about 4 months or 5 months to about 9 months after step (a), at least about 4 months after step (a) or 5 months to about 8 months after, at least about 4 months or 5 months to about 7 months after step (a), or at least about 4 months or 5 months to about 6 months after step (a) It will be implemented in a month.
[0295] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0296] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0297] In certain embodiments, the subject is a human.
[0298] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0299] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0300] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0301] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising: (a) removing peripheral blood mononuclear cells (PBMCs) from the subject; isolating and determining that at least about 20% of the PBMCs are T cells; (b) based on the determination in step (a), subsequently producing BCMA-directed chimeric antigen receptor (CAR) T cells ( and (c) administering the CAR T cells to a subject, and prior to step (a), the subject has previously received an alkylating agent for treatment of cancer. A method is provided herein. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago. In certain embodiments, the subject has previously undergone at least about 6 months to about 14 months before step (a), at least about 6 months to about 13 months before step (a), At least about 6 months to about 12 months before step (a), at least about 6 months to about 11 months before step (a), at least about 6 months to about 10 months before step (a), step (a) at least about 6 months to about 9 months before, at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months before step (a). He was receiving medication. In certain embodiments, step (b) is performed at least about 7 months to about 14 months before step (a), at least about 8 months to about 14 months before step (a), at least about 9 months to about 14 months before step (a); at least about 10 months to about 14 months before step (a); at least about 11 months to about 14 months before step (a); ) or at least about 13 months to about 14 months before step (a).
[0302] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0303] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0304] In certain embodiments, the T cells are CD8+ effector memory RA (TEMRA) (CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are TEMRA T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are TEMRA T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are TEMRA T cells. In certain embodiments of such methods, the T cells are CD3+ cells.
[0305] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0306] In another specific embodiment, the subject has previously performed at least about 4 months or 5 months to about 14 months prior to step (a), at least about 4 months or 5 months to about 14 months prior to step (a). 13 months before, at least about 4 months or 5 months to about 12 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), ) at least about 4 months or 5 months to about 10 months before step (a), at least about 4 months or 5 months to about 9 months before step (a), or at least about 4 months before step (a) or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before step (a), or at least about 4 months or 5 months to about 6 months before step (a) He had received an alkylating agent a month ago.
[0307] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma.
[0308] In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0309] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0310] In certain embodiments, the subject is a human.
[0311] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0312] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0313] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0314] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, comprising: (a) removing peripheral blood mononuclear cells (PBMCs) from the subject; (b) producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMC; and (c) administering the BCMA CAR T cells to the subject. , the patient has previously received an alkylating agent for treatment of cancer, and step (a) is performed at least about 6 months after the subject has received the alkylating agent. provided. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) extracting chimeras from the PBMCs based on the determination in step (a). The method further includes the step of subsequently producing antigen receptor (CAR) T cells. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months. In certain embodiments, step (a) occurs at least about 6 months to about 14 months after the subject received the alkylating agent, at least about 6 months to about 13 months after the subject received the alkylating agent. at least about 6 months to about 12 months after the subject received an alkylating agent, at least about 6 months to about 11 months after the subject received an alkylating agent, after the subject received an alkylating agent At least about 6 months to about 10 months after the subject received an alkylating agent, at least about 6 months to about 9 months after the subject received an alkylating agent, at least about 6 months to about 8 months after the subject received an alkylating agent or at least about 6 months to about 7 months after the subject received the alkylating agent. In certain embodiments, step (a) occurs at least about 7 months to about 14 months after the subject received the alkylating agent, at least about 8 months to about 14 months after the subject received the alkylating agent. at least about 9 months to about 14 months after the subject received an alkylating agent, at least about 10 months to about 14 months after the subject received an alkylating agent, after the subject received an alkylating agent after at least about 11 months to about 14 months, after at least about 12 months to about 14 months after the subject received an alkylating agent, or after at least about 13 months to about 14 months after the subject received an alkylating agent. It will be implemented in a month.
[0315] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0316] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0317] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0318] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0319] In another specific embodiment, step (a) comprises at least about 4 months or from 5 months to about 14 months after the subject received the alkylating agent, at least about 4 months after the subject received the alkylating agent. month or 5 months to about 13 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 12 months after the subject has received an alkylating agent, at least about 4 months or after the subject has received an alkylating agent 5 months to about 11 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 10 months after the subject has received an alkylating agent, at least about 4 months or 5 months after the subject has received an alkylating agent ~9 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent Performed about 7 months later, or at least about 4 months or 5 months to about 6 months after the subject received the alkylating agent.
[0320] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0321] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0322] In certain embodiments, the subject is a human.
[0323] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0324] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0325] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0326] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, the subject administering an alkylating agent for treatment of the cancer. and (a) determining that the subject has not received an alkylating agent for less than about 6 months prior to this determining step; (b) obtaining peripheral blood mononuclear cells (PBMCs) from the subject. isolating, the isolating step being performed at least 6 months after the alkylating agent was administered to the subject; (c) a chimeric antigen receptor (CAR) directed to BCMA from PBMCs; Provided herein are methods comprising: producing a T cell (BCMA CAR T cell); and then (d) administering the BCMA CAR T cell to a subject. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0327] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0328] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0329] In certain embodiments, the subject is a human.
[0330] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0331] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0332] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0333] In another aspect, a method of treating cancer caused by cells expressing a B cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent, the method comprising: (a) Isolating peripheral blood mononuclear cells (PBMCs) from the subject; (b) producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from PBMCs; then (c) BCMA Provided herein are methods comprising administering a CAR T cell to a subject, wherein, at the time of isolation, it is determined that the subject has been administered an alkylating agent at least about 6 months previously. . In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have been administered an alkylating agent at least about 14 months ago. In certain embodiments, the subject is at least about 6 months to about 14 months ago, at least about 6 months to about 13 months ago, at least about 6 months to about 12 months ago, at least about 6 months ago ~about 11 months ago, at least about 6 months to about 10 months ago, at least about 6 months to about 9 months ago, at least about 6 months to about 8 months ago, or at least about 6 months ago It has been determined that he received an alkylating agent approximately 7 months ago. In certain embodiments, the subject is at least about 7 months to about 14 months ago, at least about 8 months to about 14 months ago, at least about 9 months to about 14 months ago, at least about 10 months ago. ~about 14 months ago, at least about 11 months to about 14 months ago, at least about 12 months to about 14 months ago, or at least about 13 months to about 14 months ago: It has been decided that
[0334] In another specific embodiment, the subject is at least about 4 or 5 months old to about 14 months old, at least about 4 months or 5 months old to about 13 months old, at least about 4 months or 5 months old month to about 12 months ago, at least about 4 or 5 months to about 11 months ago, at least about 4 or 5 months to about 10 months ago, at least about 4 or 5 months ago ~about 9 months ago, at least about 4 or 5 months to about 8 months ago, at least about 4 or 5 months to about 7 months ago, or at least about 4 or 5 months ago It has been determined that he was given an alkylating agent approximately 6 months ago.
[0335] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0336] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0337] In certain embodiments, the subject is a human.
[0338] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0339] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0340] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0341] In another aspect, a method of treating cancer caused by cells expressing a B-cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent and receiving an alkylating agent from the patient. administering to the subject BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) produced from isolated peripheral blood mononuclear cell PBMCs, when the PBMCs are isolated; Provided herein are methods, wherein the subject last received an alkylating agent at least about 6 months before the time the PBMCs were isolated. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more Last received an alkylating agent at least about 13 months ago, or at least about 14 months ago.
[0342] In another specific embodiment, the subject has at least about 4 months or 5 months to about 14 months before, at least about 4 months or 5 months to about 13 months before the time the PBMCs are isolated. at least about 4 months or 5 months to about 12 months before the time the PBMCs are isolated; at least about 4 months or 5 months to about 11 months before the time the PBMCs are isolated; at least about 4 months or 5 months to about 10 months before the PBMCs are isolated; at least about 4 months or 5 months to about 9 months before the PBMCs are isolated; about 4 months or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before the time the PBMCs are isolated, or at least about 4 months before the time the PBMCs are isolated. Last received an alkylating agent in the last month or 5 to 6 months ago.
[0343] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0344] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0345] In certain embodiments, the subject is a human.
[0346] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0347] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0348] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0349] In another aspect, a method of treating cancer caused by cells expressing a B-cell maturation agent (BCMA) in a subject in need of treatment, the subject receiving an alkylating agent and receiving an alkylating agent from the patient. administering to the subject BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) produced from isolated peripheral blood mononuclear cell PBMCs, when the PBMCs are isolated; Provided herein are methods wherein the PBMCs contain at least about 20% T cells.
[0350] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0351] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, One or more of streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0352] In certain embodiments, the subject is a human.
[0353] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a BCMA02 scFv, eg, SEQ ID NO: 38. In certain embodiments, the BCMA CAR T cells are idecabutadiene vicleucel cells.
[0354] In certain embodiments, the subject undergoes a leukapheresis procedure to collect PBMC for production of BCMA CAR T cells prior to administration of BCMA CAR T cells to the subject.
[0355] In certain embodiments, BCMA CAR T cells are administered by intravenous infusion.
[0356] In another embodiment, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising the steps of: (a) administering an alkylating agent to the subject for treatment of a tumor or cancer; (b) (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after; and then (c) producing chimeric antigen receptor (CAR) T cells from the PBMCs. Provided herein. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later. In certain embodiments, step (b) is performed at least about 6 months to about 14 months after step (a), at least about 6 months to about 13 months after step (a), and at least about 6 months to about 13 months after step (a). at least about 6 months to about 12 months after step (a), at least about 6 months to about 10 months after step (a), after at least about 6 months to about 10 months after step (a); ), at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months after step (a). Ru. In certain embodiments, step (b) is performed at least about 7 months to about 14 months after step (a), at least about 8 months to about 14 months after step (a), and at least about 8 months to about 14 months after step (a). at least about 9 months to about 14 months after step (a), at least about 11 months to about 14 months after step (a), after at least about 11 months to about 14 months after step (a), It is carried out at least about 12 months to about 14 months after a), or at least about 13 months to about 14 months after step (a).
[0357] In another specific embodiment, step (b) is performed at least about 4 months or 5 months to about 14 months after step (a), at least about 4 months or 5 months after step (a). After about 13 months, at least about 4 months or 5 months to about 12 months after step (a), at least about 4 months or 5 months to about 11 months after step (a), after step (a) At least about 4 months or 5 months to about 10 months after a), at least about 4 months or 5 months to about 9 months after step (a), at least about 4 months after step (a) or 5 months to about 8 months after step (a), at least about 4 months or 5 months to about 7 months after step (a), at least about 4 months or 5 months to about 6 months after step (a) It will be implemented in a month.
[0358] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0359] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0360] In certain embodiments, the subject is a human.
[0361] In another aspect, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. and (b) subsequently producing chimeric antigen receptor (CAR) T cells from PBMCs based on the determination in step (a); Provided herein are methods in which the patient has previously received an alkylating agent for the treatment of a tumor or cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago. In certain embodiments, the subject has previously undergone at least about 6 months to about 14 months before step (a), at least about 6 months to about 13 months before step (a), At least about 6 months to about 12 months before step (a), at least about 6 months to about 11 months before step (a), at least about 6 months to about 10 months before step (a), step (a) at least about 6 months to about 9 months before, at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months before step (a). was receiving medication. In certain embodiments, the subject has previously undergone at least about 7 months to about 14 months before step (a), at least about 8 months to about 14 months before step (a), At least about 9 months to about 14 months before step (a), at least about 10 months to about 14 months before step (a), at least about 11 months to about 14 months before step (a), step (a) or at least about 13 months to about 14 months before step (a).
[0362] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0363] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0364] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0365] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0366] In another specific embodiment, the subject has previously performed at least about 4 months or 5 months to about 14 months prior to step (a), at least about 4 months or 5 months to about 14 months prior to step (a). 13 months before, at least about 4 months or 5 months to about 12 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), ) at least about 4 months or 5 months to about 10 months before step (a), at least about 4 months or 5 months to about 9 months before step (a), or at least about 4 months before step (a) or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before step (a), or at least about 4 months or 5 months to about 6 months before step (a) He had received an alkylating agent a month ago.
[0367] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0368] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0369] In certain embodiments, the subject is a human.
[0370] In another embodiment, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising the steps of: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; the subject has previously received an alkylating agent for treatment of a tumor or cancer; step (a) includes the step of producing an antigen receptor (CAR) T cell; Provided herein are methods that are performed after at least about 6 months. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) extracting chimeras from the PBMCs based on the determination in step (a). The method further includes the step of subsequently producing antigen receptor (CAR) T cells. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months. In certain embodiments, step (a) occurs at least about 6 months to about 14 months after the subject received the alkylating agent, at least about 6 months to about 13 months after the subject received the alkylating agent. at least about 6 months to about 12 months after the subject received an alkylating agent, at least about 6 months to about 11 months after the subject received an alkylating agent, after the subject received an alkylating agent At least about 6 months to about 10 months after the subject received an alkylating agent, at least about 6 months to about 9 months after the subject received an alkylating agent, at least about 6 months to about 8 months after the subject received an alkylating agent or at least about 6 months to about 7 months after the subject received the alkylating agent. In certain embodiments, step (a) occurs at least about 7 months to about 14 months after the subject received the alkylating agent, at least about 8 months to about 14 months after the subject received the alkylating agent. at least about 9 months to about 14 months after the subject received an alkylating agent, at least about 10 months to about 14 months after the subject received an alkylating agent, after the subject received an alkylating agent after at least about 11 months to about 14 months, after at least about 12 months to about 14 months after the subject received an alkylating agent, or after at least about 13 months to about 14 months after the subject received an alkylating agent. It will be implemented in a month.
[0371] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0372] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0373] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0374] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0375] In another specific embodiment, step (a) comprises at least about 4 months or from 5 months to about 14 months after the subject received the alkylating agent, at least about 4 months after the subject received the alkylating agent. month or 5 months to about 13 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 12 months after the subject has received an alkylating agent, at least about 4 months or after the subject has received an alkylating agent 5 months to about 11 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 10 months after the subject has received an alkylating agent, at least about 4 months or 5 months after the subject has received an alkylating agent ~9 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent Performed about 7 months later, or at least about 4 months or 5 months to about 6 months after the subject received the alkylating agent.
[0376] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0377] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0378] In certain embodiments, the subject is a human.
[0379] In another aspect, a method of producing a chimeric antigen receptor (CAR) T cell from a subject, the subject being administered an alkylating agent for the treatment of a tumor or cancer, the subject comprising: a. determining that the subject has not been administered an alkylating agent for less than about 6 months prior to determining; b. isolating peripheral blood mononuclear cells (PBMC) from the subject; and c. Provided herein are methods comprising producing receptor (CAR) T cells. In certain embodiments, in step (a), the subject is less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, about 11 months prior to said determining step. have not been administered an alkylating agent for less than about 12 months, less than about 13 months, or less than about 14 months.
[0380] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0381] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0382] In certain embodiments, the subject is a human.
[0383] In another aspect, a method of producing a chimeric antigen receptor (CAR) T cell from a subject, the subject receiving an alkylating agent for the treatment of a tumor or cancer, the method comprising: isolating blood mononuclear cells (PBMCs); then (b) producing chimeric antigen receptor (CAR) T cells from the PBMCs; at the time of isolation, the subject has been at least about 6 months old. Provided herein are methods in which it is determined that an alkylating agent has been administered. In certain embodiments, the subject is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months. , or has been determined to have received an alkylating agent at least about 14 months ago. In certain embodiments, the subject is at least about 6 months to about 14 months ago, at least about 6 months to about 13 months ago, at least about 6 months to about 12 months ago, at least about 6 months ago ~about 11 months ago, at least about 6 months to about 10 months ago, at least about 6 months to about 9 months ago, at least about 6 months to about 8 months ago, or at least about 6 months ago It has been determined that he received an alkylating agent approximately 7 months ago. In certain embodiments, the subject is at least about 7 months to about 14 months ago, at least about 8 months to about 14 months ago, at least about 9 months to about 14 months ago, at least about 10 months ago. ~about 14 months ago, at least about 11 months to about 14 months ago, at least about 12 months to about 14 months ago, or at least about 13 months to about 14 months ago: It has been decided that
[0384] In another specific embodiment, the subject is at least about 4 or 5 months old to about 14 months old, at least about 4 months or 5 months old to about 13 months old, at least about 4 months or 5 months old month to about 12 months ago, at least about 4 or 5 months to about 11 months ago, at least about 4 or 5 months to about 10 months ago, at least about 4 or 5 months ago ~about 9 months ago, at least about 4 or 5 months to about 8 months ago, at least about 4 or 5 months to about 7 months ago, or at least about 4 or 5 months ago It has been determined that he was given an alkylating agent approximately 6 months ago.
[0385] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0386] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0387] In certain embodiments, the subject is a human.
[0388] In another aspect, a method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject, wherein at least about 20% of the PBMCs are T cells. and (b) subsequently manufacturing CAR T cells from the PBMCs based on the determination in step (a); Provided herein are methods in which the method includes a curing agent. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously undergone step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago. In certain embodiments, the subject has previously undergone at least about 6 months to about 14 months before step (a), at least about 6 months to about 13 months before step (a), At least about 6 months to about 12 months before step (a), at least about 6 months to about 11 months before step (a), at least about 6 months to about 10 months before step (a), step (a) at least about 6 months to about 9 months before, at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months before step (a). He was receiving medication. In certain embodiments, step (b) is performed at least about 7 months to about 14 months before step (a), at least about 8 months to about 14 months before step (a), at least about 9 months to about 14 months before step (a); at least about 10 months to about 14 months before step (a); at least about 11 months to about 14 months before step (a); ) or at least about 13 months to about 14 months before step (a).
[0389] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0390] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0391] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0392] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0393] In another specific embodiment, the subject has previously performed at least about 4 months or 5 months to about 14 months prior to step (a), at least about 4 months or 5 months to about 14 months prior to step (a). 13 months before, at least about 4 months or 5 months to about 12 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), ) at least about 4 months or 5 months to about 10 months before step (a); at least about 4 months or 5 months to about 9 months before step (a); at least about 4 months before step (a) or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before step (a), or at least about 4 months or 5 months to about 6 months before step (a) Had received an alkylating agent a month ago.
[0394] In certain embodiments, the tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenocortical cancer, thyroid cancer, nasopharyngeal cancer, melanoma, skin cancer, colorectal cancer, tendonoma, adhesion carcinoma. round cell tumor, endocrine tumor, Ewing sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia disease, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse Large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic Leukemia, aggressive NK cell leukemia, adult T lymphocyte leukemia / lymphoma, extranodal NK / T lymphocyte leukemia, nasal / intestinal T lymphocyte lymphoma, hepatosplenic T lymphocyte lymphoma, blast NK cell lymphoma, Mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T lymphocyte lymphoma, peripheral T lymphocyte lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin lymphoma , non-Hodgkin's lymphoma, or multiple myeloma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0395] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0396] In certain embodiments, the subject is a human.
[0397] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) administering an alkylating agent to the subject for the treatment of cancer; (b) isolating peripheral blood mononuclear cells (PBMCs) from the subject at least about 6 months after step (a); and (c) producing BCMA CAR T cells from the PBMCs. , methods are provided herein. In certain embodiments, step (b) is at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months after step (a). month, at least about 13 months, or at least about 14 months later. In certain embodiments, step (b) is performed at least about 6 months to about 14 months after step (a), at least about 6 months to about 13 months after step (a), and at least about 6 months to about 13 months after step (a). at least about 6 months to about 12 months after step (a), at least about 6 months to about 10 months after step (a), after at least about 6 months to about 10 months after step (a); ), at least about 6 months to about 8 months after step (a), at least about 6 months to about 7 months after step (a) . In certain embodiments, step (b) is performed at least about 7 months to about 14 months after step (a), at least about 8 months to about 14 months after step (a), and at least about 8 months to about 14 months after step (a). at least about 9 months to about 14 months after step (a), at least about 11 months to about 14 months after step (a), after at least about 11 months to about 14 months after step (a), after at least about 11 months to about 14 months after step (a) ) or at least about 13 months to about 14 months after step (a).
[0398] In another specific embodiment, step (b) is performed at least about 4 months or 5 months to about 14 months after step (a), at least about 4 months or 5 months after step (a). After about 13 months, at least about 4 months or 5 months to about 12 months after step (a), at least about 4 months or 5 months to about 11 months after step (a), after step (a) At least about 4 months or 5 months to about 10 months after a), at least about 4 months or 5 months to about 9 months after step (a), at least about 4 months after step (a) or 5 months to about 8 months after, at least about 4 months or 5 months to about 7 months after step (a), or at least about 4 months or 5 months to about 6 months after step (a) It will be implemented in a month.
[0399] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0400] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0401] In certain embodiments, the subject is a human.
[0402] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0403] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; , determining that at least about 20% of the PBMCs are T cells; then (b) based on the determination in step (a), subsequently producing BCMA CAR T cells from the PBMCs; step (a) Provided herein are methods in which the subject has previously received an alkylating agent for treatment of cancer. In certain embodiments, the subject has previously received an alkylating agent at least about 6 months prior to step (a). In certain embodiments, the subject has previously attended step (a) for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months. month, at least about 13 months, or at least about 14 months ago. In certain embodiments, the subject has previously received at least about 6 months to about 14 months before step (a), at least about 6 months to about 13 months before step (a), at least about 6 months to about 12 months before step (a); at least about 6 months to about 11 months before step (a); at least about 6 months to about 10 months before step (a); ), at least about 6 months to about 8 months after step (a), or at least about 6 months to about 7 months before step (a) He had been given a chemical. In certain embodiments, step (b) is performed at least about 7 months to about 14 months before step (a), at least about 8 months to about 14 months before step (a), at least about 9 months to about 14 months before step (a); at least about 10 months to about 14 months before step (a); at least about 11 months to about 14 months before step (a); ) or at least about 13 months to about 14 months before step (a).
[0404] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0405] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0406] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0407] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0408] In another specific embodiment, the subject has previously been at least about 4 months or 5 months to about 14 months before step (a), at least about 4 months or 5 months before step (a). about 13 months before, at least about 4 months or 5 months to about 12 months before step (a), at least about 4 months or 5 months to about 11 months before step (a), about 12 months before step (a); At least about 4 months or 5 months to about 10 months before a), at least about 4 months or 5 months to about 9 months before step (a), at least about 4 months before step (a) or 5 months to about 8 months before, at least about 4 months or 5 months to about 7 months before step (a), or at least about 4 months or 5 months to about 6 months before step (a) Had received an alkylating agent in the previous month.
[0409] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0410] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0411] In certain embodiments, the subject is a human.
[0412] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0413] In another aspect, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the method comprising: (a) isolating peripheral blood mononuclear cells (PBMCs) from the subject; and (b) producing BCMA CAR T cells from PBMCs; the subject has previously received an alkylating agent for treatment of cancer; step (a) Provided herein are methods that are performed at least about 6 months after receiving the agent. In certain embodiments, step (a) further comprises determining that at least about 20% of the PBMCs are T cells; step (b) extracting chimeras from the PBMCs based on the determination in step (a). The method further includes the step of subsequently producing antigen receptor (CAR) T cells. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months. In certain embodiments, step (a) occurs at least about 6 months to about 14 months after the subject received the alkylating agent, at least about 6 months to about 13 months after the subject received the alkylating agent. at least about 6 months to about 12 months after the subject received an alkylating agent, at least about 6 months to about 11 months after the subject received an alkylating agent, after the subject received an alkylating agent At least about 6 months to about 10 months after the subject received an alkylating agent, at least about 6 months to about 9 months after the subject received an alkylating agent, at least about 6 months to about 8 months after the subject received an alkylating agent or at least about 6 months to about 7 months after the subject received the alkylating agent. In certain embodiments, step (a) occurs at least about 7 months to about 14 months after the subject received the alkylating agent, at least about 8 months to about 14 months after the subject received the alkylating agent. at least about 9 months to about 14 months after the subject received an alkylating agent, at least about 10 months to about 14 months after the subject received an alkylating agent, after the subject received an alkylating agent after at least about 11 months to about 14 months, after at least about 12 months to about 14 months after the subject received an alkylating agent, or after at least about 13 months to about 14 months after the subject received an alkylating agent. It will be implemented in a month.
[0414] In another specific embodiment, step (a) comprises at least about 4 months or from 5 months to about 14 months after the subject received the alkylating agent, at least about 4 months after the subject received the alkylating agent. month or 5 months to about 13 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 12 months after the subject has received an alkylating agent, at least about 4 months or after the subject has received an alkylating agent 5 months to about 11 months after the subject has received an alkylating agent, at least about 4 months or 5 months to about 10 months after the subject has received an alkylating agent, at least about 4 months or 5 months after the subject has received an alkylating agent ~9 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent; ~8 months after the subject has received an alkylating agent Performed about 7 months later, or at least about 4 months or 5 months to about 6 months after the subject received the alkylating agent.
[0415] In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% determining that ~28%, 15% to about 29%, or 15% to about 30% are T cells.
[0416] In certain embodiments of the methods presented herein, the T cells include CD3+ cells. In certain embodiments, the T cells are CD3+ cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, determining that 24%, 25%, 26%, 27%, 28%, 29%, or 30% are T CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% determining that ~20%, 28% ~20%, 29% ~20%, or 30% ~20% are CD3+ T cells, eg, CD45+ / CD3+ T cells. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~about 28%, 15% to about 29%, or 15% to about 30% are CD3+ T cells.
[0417] In certain embodiments, the T cells are CD8+ effector memory RA (T EMRA )(CCR7- / CD45RA+) T cells. In certain embodiments of the methods presented herein, the method comprises at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 20%, 16% to about 20%, 17% to about 20%, 18% to about 20%, 19% to about 20%, 20 %~about 20%, 21%~about 20%, 22%~about 20%, 23%~about 20%, 24%~about 20%, 25%~about 20%, 26%~about 20%, 27% ~20%, 28%~20%, 29%~20%, or 30%~20% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments, the method provides at least about 15% to about 16%, 15% to about 17%, 15% to about 18%, 15% to about 19%, 15% to about 20%, 15% of PBMC. %~about 21%, 15%~about 22%, 15%~about 23%, 15%~about 24%, 15%~about 25%, 15%~about 26%, 15%~about 27%, 15% ~28%, 15%~29%, or 15%~30% T EMRA The method includes a step of determining that the cell is a T cell. In certain embodiments of such methods, the T cells are CD3+ cells.
[0418] In the methods presented herein, the determining step may be performed using standard techniques well known to those skilled in the relevant art. For example, in the methods presented herein, the step of determining includes the techniques utilized in Example 2 (e.g., by polychromatic flow cytometry for markers associated with T cell differentiation, memory, senescence, and exhaustion). This may be done by using techniques such as immunophenotyping of PBMCs.
[0419] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0420] In certain embodiments, the alkylating agent is altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan (e.g., melphalan hydrochloride), oxali one or more of platinum, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin. In certain embodiments, the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evophosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa. In certain embodiments, the alkylating agent is cyclophosphamide.
[0421] In certain embodiments, the subject is a human.
[0422] In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises an antibody or antibody fragment that targets BCMA. In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises a single chain Fv antibody or antibody fragment (scFv). In certain embodiments, the BCMA CAR T cell comprises a BCMA-directed CAR, and the BCMA-directed CAR comprises BCMA02 scFv, eg, SEQ ID NO: 38.
[0423] In another embodiment, a method of producing BCMA-directed chimeric antigen receptor (CAR) T cells (BCMA CAR T cells) from a subject, the subject receiving an alkylating agent for the treatment of cancer. a. determining that the subject has not been administered an alkylating agent for less than about 6 months prior to the determining step; b. isolating peripheral blood mononuclear cells (PBMC) from the subject; Provided herein are methods comprising then producing BCMA CAR T cells from c.PBMC. In certain embodiments, step (a) includes the subject receiving the alkylating agent for at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, conducted after at least about 12 months, at least about 13 months, or at least about 14 months.
[0424] In certain embodiments, the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma. In certain embodiments, the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, progenitor B lymphoblastic lymphoma, or mantle cell lymphoma. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma. In certain embodiments, the multiple myeloma is high-risk multiple myeloma, and the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse. . In certain embodiments, the multiple myeloma is not R-ISS Stage III disease.
[0425] In certain embodim...
Claims
1. 1. Use of chimeric antigen receptor (CAR) T cells in the manufacture of a medicament for treating a tumor or cancer in a subject in need thereof, said medicament comprising chimeric antigen receptor (CAR) T cells obtained from a sample comprising peripheral blood mononuclear cells (PBMCs) isolated from said subject, wherein said subject has previously received an alkylating agent for treatment of the tumor or cancer at least about 6 months prior to said isolation.
2. 2. The use of claim 1, wherein the subject previously received an alkylating agent at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months prior to said isolation.
3. 3. The use of claim 1 or 2, wherein the isolation is performed at least about 6 months after the subject has received an alkylating agent.
4. The use according to any one of claims 1 to 3, wherein at least about 20% of the PBMCs are T cells.
5. 5. The use of claim 4, wherein the isolating is performed at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months after the subject has received an alkylating agent.
6. 6. The use of any one of claims 1 to 5, wherein the subject has not been administered an alkylating agent for less than about 6 months prior to said isolation.
7. 7. The use of claim 6, wherein the subject has been determined to have not been administered an alkylating agent for less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, less than about 11 months, less than about 12 months, less than about 13 months, or less than about 14 months prior to said isolation.
8. 8. The use of any one of claims 1 to 7, wherein at the time of said isolation, said subject has been determined to have been administered an alkylating agent at least about 6 months previously.
9. 9. The use of claim 8, wherein the subject has been determined to have been administered an alkylating agent at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months ago.
10. The tumor or cancer is selected from the group consisting of lymphoma, lung cancer, breast cancer, prostate cancer, adrenal cortical carcinoma, thyroid cancer, nasopharyngeal carcinoma, melanoma, skin cancer, colorectal cancer, desmoid tumor, adhesive small round cell tumor, endocrine tumor, Ewing's sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms' tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, lymphoma, diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T-lymphocytic leukemia / lymphoma, extranodal NK / T-lymphocytic leukemia, nasal / enteropathic T-lymphocytic lymphoma, hepatosplenic T 10. The use according to any one of claims 1 to 9, wherein the tumor is lymphocytic lymphoma, blastic NK cell lymphoma, mycosis fungoides, Sezary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T-lymphocytic lymphoma, peripheral T-lymphocytic lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or multiple myeloma.
11. 11. The use of claim 10, wherein the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma.
12. 12. The use of claim 11, wherein the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma.
13. The use according to claim 11, wherein the cancer is multiple myeloma.
14. The use according to claim 13, wherein the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma.
15. The use according to claim 13, wherein the multiple myeloma is high-risk multiple myeloma, wherein the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterised by early relapse.
16. 16. The use of any one of claims 1 to 15, wherein the alkylating agent is one or more of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin.
17. 17. The use of claim 16, wherein the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evofosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa.
18. 18. The use of claim 17, wherein the alkylating agent is cyclophosphamide.
19. 19. The use according to any one of claims 1 to 18, wherein the subject is a human.
20. 20. The use of any one of claims 1 to 19, wherein the subject undergoes an apheresis or leukapheresis procedure to collect PBMCs for the manufacture of the CAR T cells prior to administration of the CAR T cells to the subject.
21. 21. The use of any one of claims 1 to 20, wherein the CAR T cells are administered by intravenous infusion.
22. 22. The use according to any one of claims 1 to 21, wherein the sample is an apheresis or leukapheresis sample.
23. 23. The use according to any one of claims 1 to 22, wherein the cancer is caused by cells expressing B-cell maturation agent (BCMA).
24. 24. The use according to any one of claims 1 to 23, wherein the chimeric antigen receptor (CAR) T cells are directed against a B cell maturation agent (BCMA CAR T cells).
25. 25. The use of claim 24, wherein the BCMA CAR T cells comprise a CAR directed to BCMA, and the BCMA directed CAR comprises an antibody or antibody fragment that targets BCMA.
26. 25. The use of claim 24, wherein the BCMA CAR T cells comprise a CAR directed against BCMA, and the CAR directed against BCMA comprises a single chain Fv antibody or antibody fragment (scFv).
27. 1. A method of producing chimeric antigen receptor (CAR) T cells from a subject, comprising: (a) isolating a sample comprising peripheral blood mononuclear cells (PBMCs) from said subject; and then (b) producing chimeric antigen receptor (CAR) T cells from the sample comprising the PBMCs; The method, wherein prior to step (a), the subject has previously received an alkylating agent for the treatment of a tumor or cancer.
28. 28. The method of claim 27, wherein the subject previously received an alkylating agent at least about 6 months prior to step (a).
29. 29. The method of claim 27 or 28, wherein the subject previously received an alkylating agent at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months prior to step (a).
30. 30. The method of any one of claims 27 to 29, wherein step (a) is performed at least about 6 months after the subject has received an alkylating agent.
31. 31. The method of any one of claims 27 to 30, wherein step (a) further comprises determining that at least about 20% of the PBMCs are T cells.
32. 32. The method of any one of claims 27 to 31, wherein step (b) further comprises subsequently producing chimeric antigen receptor (CAR) T cells from the PBMCs based on the determination in step (a).
33. 33. The method of claim 31 or 32, wherein the determining in step (a) is performed at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months after the subject has received an alkylating agent.
34. 34. The method of any one of claims 27 to 33, further comprising the step of determining that the subject has not been administered an alkylating agent for less than about 6 months prior to the isolation in step (a).
35. 35. The method of claim 34, wherein the subject has been determined to have not been administered an alkylating agent for less than about 7 months, less than about 8 months, less than about 9 months, less than about 10 months, less than about 11 months, less than about 12 months, less than about 13 months, or less than about 14 months prior to the isolating step.
36. 36. The method of any one of claims 27 to 35, wherein at the time of isolation in step (a), the subject has been determined to have been administered an alkylating agent at least about 6 months previously.
37. 37. The method of claim 36, wherein it has been determined that the subject was administered an alkylating agent at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, or at least about 14 months ago.
38. The tumor or cancer is lymphoma, lung cancer, breast cancer, prostate cancer, adrenal cortical carcinoma, thyroid cancer, nasopharyngeal carcinoma, melanoma, skin cancer, colorectal cancer, desmoid tumor, adhesive small round cell tumor, endocrine tumor, Ewing's sarcoma, peripheral primitive neuroectodermal tumor, solid germ cell tumor, hepatoblastoma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, Wilms' tumor, glioblastoma, myxoma, fibroma, lipomatous chronic lymphocytic leukemia (small lymphocytic lymphoma), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, MALT lymphoma, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Large B-cell lymphoma, diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma, T-lymphocytic prolymphocytic leukemia, T-lymphocytic large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T-lymphocytic leukemia / lymphoma, extranodal NK / T-lymphocytic leukemia, nasal / enteropathic T-lymphocytic lymphoma, hepatosplenic T-lymphocytic lymphoma 38. The method of any one of claims 27 to 37, wherein the tumor is selected from the group consisting of cutaneous anaplastic large cell lymphoma, blastic NK cell lymphoma, mycosis fungoides, Sezary syndrome, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papuloma, angioimmunoblastic T-lymphocytic lymphoma, peripheral T-lymphocytic lymphoma (unspecified), anaplastic large cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or multiple myeloma.
39. 39. The method of claim 38, wherein the cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma.
40. 40. The method of claim 39, wherein the cancer is non-Hodgkin's lymphoma, and the non-Hodgkin's lymphoma is Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma.
41. 40. The method of claim 39, wherein the cancer is multiple myeloma.
42. 42. The method of claim 41, wherein the multiple myeloma is high-risk multiple myeloma or relapsed and refractory multiple myeloma.
43. 42. The method of claim 41, wherein the multiple myeloma is high-risk multiple myeloma, wherein the high-risk multiple myeloma is R-ISS stage III disease and / or disease characterized by early relapse.
44. 44. The method of any one of claims 27 to 43, wherein the alkylating agent is one or more of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, evofosfamide, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, platinum, procarbazine, streptozocin, temozolomide, thiotepa, and trabectedin.
45. 45. The method of claim 44, wherein the alkylating agent is one or more of bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, evofosfamide, ifosfamide, oxaliplatin, platinum, procarbazine, and thiotepa.
46. 46. The method of claim 45, wherein the alkylating agent is cyclophosphamide.
47. 47. The method of any one of claims 27 to 46, wherein the subject is a human.
48. 48. The method of any one of claims 27-47, wherein the subject undergoes an apheresis or leukapheresis procedure to collect PBMCs for the manufacture of CAR T cells prior to administration of the CAR T cells to the subject.
49. 49. The method of any one of claims 27 to 48, wherein the sample is an apheresis or leukapheresis sample.
50. 50. The method of any one of claims 27 to 49, wherein the cancer is caused by cells that express B-cell maturation agent (BCMA).
51. 51. The method of any one of claims 27 to 50, wherein the chimeric antigen receptor (CAR) T cells are directed against a B cell maturation agent (BCMA CAR T cells).
52. 52. The method of claim 51 , wherein the BCMA CAR T cell comprises a CAR directed to BCMA, and the BCMA directed CAR comprises an antibody or antibody fragment that targets BCMA.
53. 52. The method of claim 51 , wherein the BCMA CAR T cell comprises a CAR directed to BCMA, and the CAR directed to BCMA comprises a single chain Fv antibody or antibody fragment (scFv).
54. 1. A method of determining whether a subject having cancer can be treated with CAR T therapy in a sample from the subject, comprising determining a percentage of CD3+ T cells in the subject relative to the number of PBMCs, wherein (i) if the subject has less than about 20% CD3+ T cells relative to the number of PBMCs, then CAR T therapy is not administered to the subject, and (ii) if the subject has more than about 20% CD3+ T cells relative to the number of PBMCs, then CAR T therapy is administered to the subject.
55. 1. Use of chimeric antigen receptor (CAR) T cells in the manufacture of a medicament in a subject, wherein prior to administering the CAR T cells, it is determined that the percentage of CD3+ T cells in the subject relative to the number of PMBCs is greater than about 20%, and then the CAR T cells are administered.
56. 56. The method or use of claim 54 or 55, wherein the CD3+ T cells are CD45+ / CD3+ T cells.
57. 1. A method for determining an optimal washout period for initiating treatment for the treatment of a condition in a subject following a previous exposure, comprising: receiving prior medical history data for each of the plurality of subjects; deriving left-censored treatment data, including washout periods and events or censoring, for each of said subjects from prior treatment history data; inverting the time scale of the left-censored treatment data to obtain right-censored treatment data; fitting the right-censored treatment data to a time-to-event (TTE) model relating one or more variables of interest to time since exposure to a prior exposure; calculating a maximally selected log-rank statistic across multiple cutoffs within predefined percentile ranges for continuous variables within one or more variables of interest; identifying one or more variables having a maximally selected log-rank statistic less than a first predefined threshold and an associated cutoff for continuous variables within the one or more variables of interest; computing a test statistic for each of the (n-1) stratum relative to a reference stratum for ordinal or categorical variables within one or more variables of interest; identifying one or more variables and associated strata having a test statistic below a second predefined threshold against a reference stratum for ordinal or categorical variables within the one or more variables of interest; and The method includes determining an optimal washout period for treatment based on a cutoff for the median value of subjects below the predefined threshold and the median value of subjects above the predefined threshold, the minimum value being below a predefined threshold.
58. 58. The method of claim 57, further comprising providing the determined optimal washout period.
59. 59. The method of claim 58, wherein providing the determined optimal washout period comprises one or more of the following steps: displaying the determined optimal washout period on an electronic visual display, storing the determined optimal washout period on a physical persistence, loading the determined optimal washout period into memory, or transmitting the determined optimal washout period over a network to a remote computing device.
60. 60. The method of any one of claims 57 to 59, wherein the TTE model is a proportional hazards model.
61. 61. The method of any one of claims 57 to 60, wherein the TTE model is a Cox proportional hazards model.
62. 62. A method according to any one of claims 57 to 61, wherein one or more of the steps of receiving, deriving, inverting, applying, first or second calculating, first or second identifying, and determining are performed by at least one data processor forming part of at least one computing device.
63. 63. The method of any one of claims 57 to 62, wherein the previous exposure is a previous treatment.
64. 64. The method of claim 63, wherein the previous exposure and treatment are different types of therapy.
65. 65. The method of claim 64, wherein the previous exposure is to treat a condition different from the condition treated by the treatment.
66. 65. The method of claim 64, wherein the previous exposure is to treat the same condition as the condition treated by the treatment.
67. 67. The method of claim 66, wherein the previous exposure and treatment are for treating the same condition and are the same type of treatment.
68. 67. The method of claim 66, wherein the treatment is a second or subsequent line treatment and the previous exposure is an earlier line treatment.
69. 69. The method of any one of claims 57 to 68, which informs (i) when the subject should undergo treatment following a previous exposure, or (ii) exclusion criteria in a clinical trial.
70. 70. The method of any one of claims 57 to 69, wherein the treatment and / or previous exposure is radiation therapy, chemotherapy, immunotherapy, surgery, transplantation, gene therapy, or cell therapy.
71. 71. The method of any one of claims 57 to 70, wherein the condition is cancer, an immune disease (e.g., an autoimmune disease), a cardiovascular disease, a fibrotic disease, an infectious disease, or a neurological condition.
72. 72. The method of any one of claims 57 to 71, wherein the condition is a condition that can be treated by stimulating the immune system, such as cancer and infectious diseases, and the treatment is a therapy that stimulates or enhances the immune system, such as immunotherapy and cell therapy.
73. 73. The method of any one of claims 57 to 72, wherein the condition is cancer and the treatment is a cell therapy, e.g., CART.
74. 74. The method of claim 73, wherein the previous exposure is a previous treatment, and the previous treatment is a previous cancer therapy.
75. 75. The method of claim 74, wherein the cancer is multiple myeloma, the treatment is BCMA CAR T cell therapy, and the prior treatment is a prior cancer treatment for multiple myeloma.
76. 76. The method of claim 75, wherein the previous treatment is alkylating agent therapy.
77. 77. The method of any one of claims 57 to 76, wherein the previous exposure is not a previous treatment.
78. 78. The method of claim 77, wherein the previous exposure is an event that can negatively impact treatment.
79. 79. The method of claim 78, wherein the previous exposure is a previous state.
80. 80. The method of claim 79, wherein the previous condition is an inflammatory condition or an infectious disease.
81. 55. The method of claim 54, further comprising calculating the timing of administration of treatment after the previous exposure (i.e., the washout period) using the method of any one of claims 57 to 80.
82. at least one data processor; and A memory storing instructions which, when executed by said at least one data processor, perform the method of any one of claims 57 to 80. A system including:
83. 81. A non-transitory computer program product storing instructions which, when executed by at least one computing device, performs the method of any one of claims 57 to 80.
